Navigation Links
Vical Completes Enrollment and Reports Positive Interim Data in CMV Vaccine Phase 2 Trial
Date:11/12/2008

SAN DIEGO, Nov. 12 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL) announced today that the company has completed enrollment of subjects in a Phase 2 trial of its therapeutic DNA vaccine designed to prevent cytomegalovirus (CMV) reactivation and disease in immunosuppressed stem cell transplant recipients. An interim analysis of immunogenicity data for the first 33 transplant recipients in the recipient-only arm of the study showed significant (p<0.05) post-transplant enhancement of CMV-specific T-cell responses in subjects receiving vaccine compared with subjects receiving placebo.

"These patients are highly immunosuppressed after transplant and, due to pre-existing infection, are at risk of CMV reactivation and the associated disease," said Ronald B. Moss, M.D., Vical's Vice President of Clinical Development. "The inducement of CMV-specific T-cell responses after transplant is encouraging, as others have noted that T-cell responses may be predictive of better control of CMV reactivation and disease. These encouraging immunogenicity data should translate into clinical benefit, and should be confirmed by clinical efficacy results in the second quarter of 2009."

The company conducted an interim immunogenicity analysis on post-transplant sera from the first 47 stem cell transplant recipients (33 in the recipient-only arm and 14 in the donor-recipient arm). The resulting data were analyzed by treatment group, but clinical sites and trial participants remain blinded to individual treatment codes. The results indicated significant enhancement of CMV-specific immunity in the recipient-only arm as measured by T-cell responses to the two CMV antigens targeted by the vaccine: pp65 (p<0.05) and gB (p<0.05). Results for the
'/>"/>

SOURCE Vical Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. U.S. Navy and U.S. Army to Develop Dengue DNA Vaccine Formulated With Vicals Vaxfectin(R) Adjuvant
2. Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months
3. First Published Study of New HPV Test for Developing Countries Shows High Accuracy in Predicting Cervical Disease
4. Karolinska Institutet to Test Vicals Vaxfectin(R) Adjuvant With Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control
5. Karolinska Institute to Test Vicals Vaxfectin(R) Adjuvant with Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control
6. Vical Announces Breakthrough for Pandemic Influenza DNA Vaccines With Preliminary Human Data
7. Vical Advances RapidResponse(TM) DNA Vaccine Platform Under $6 Million Grant from NIH
8. Vical Receives $6.3 Million Payment for Continued Funding of Allovectin-7(R) Phase 3 Trial
9. Ending Cervical Cancer Featured at Summit; QIAGEN CEO Issues a Call to Global Women Leaders
10. Promise of Vicals CMV Vaccine Noted by Independent Experts
11. Study Finds QIAGENs HPV Test Offers Greater Long-term Protection From Cervical Disease Than the Pap
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 2014 In today,s increasingly global marketplace ... to reflect the needs of a global marketplace ... the needs of key stakeholders while recognizing regional ... According to recent research by benchmarking firm, Best ... companies averaged more than $100,000 in annual spending ...
(Date:12/19/2014)...  Monarch America Inc. (OTCQB: CANK) ("Monarch America" or ... provide this review of the Company,s recent achievements and ... "Over this past year, we achieved many of our ... to say that Monarch America is in a stronger ... been," stated Eric Hagen , CEO of Monarch ...
(Date:12/19/2014)... FORT WORTH, Texas , December 18, 2014 ... is a networked software application/module that is used ... and related images. RIS comprises a patient tracking ... tracking system. The integration of RIS with HIS ... is used for patient registration and patient scheduling, ...
Breaking Medicine Technology:Building a Best-in-Class Pharma Global Brand Website 2Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 2Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 3The Global Radiology Information Systems Market is Expected to Grow at a CAGR of 7.5% from 2014 to 2019 2The Global Radiology Information Systems Market is Expected to Grow at a CAGR of 7.5% from 2014 to 2019 3
... reduce the use of mechanical ventilation with premature infants in ... affect those children,s outcomes while reducing the cost of care, ... The team, led by Bernadette Levesque, MD, ... and the Neonatal Intensive Care Unit (NICU) at St. Elizabeth,s ...
... SPRING, Md., June 10, 2011 The U.S. Food ... Merck,s redesigned drug container labels that include a new ... on product and strength differentiation. (Logo: ... the revision of 34 container labels for 16 solid ...
Cached Medicine Technology:Guidelines for Ventilator Use Help Premature Infants Breathe Easier 2Guidelines for Ventilator Use Help Premature Infants Breathe Easier 3FDA Approves Redesigned Labels for Some Merck Drugs 2
(Date:12/19/2014)... December 20, 2014 Today, Balfleet.com ... special-occasion outfits, announces its formal dress promotion. All the ... up to 60% off. , Balfleet.com is well-known for ... bridesmaid dresses, prom dresses, cocktail dresses and more. Its ... 30-day money-back guarantee, and they can create an elegant ...
(Date:12/19/2014)... Energy Textiles is excited to ... Celliant, the world’s leading responsive textile, can now ... There are a number of benefits to wearing ... and balanced body temperature; which can lead to ... enhanced athletic performance; and overall wellness. In addition, ...
(Date:12/19/2014)... (PRWEB) December 19, 2014 Eufaula, Oklahoma, ... to Lake Eufaula, the state’s largest lake with more ... town is home to a little more than 3,000 ... P.M. on Saturday, the 6th of December. , Featuring ... way through downtown Eufaula on Main Street. Narconon ...
(Date:12/19/2014)... The print component of Vision and ... of the Toronto Star, with a circulation of approximately ... digital component is distributed nationally through a vast social ... sites and partner outlets. To explore the digital version ... publication features an exclusive interview with Mark DeMontis ...
(Date:12/19/2014)... FRIDAY, Dec. 19, 2014 (HealthDay News) -- Potentially illness-causing ... herbs bought at farmers markets, according to a new ... almost 50 vendors from 13 farmers markets in Los ... Seattle area. Out of almost 150 samples tested, 24 ... positive for salmonella, according to the researchers. Both ...
Breaking Medicine News(10 mins):Health News:Balfleet.com Announces Its Formal Dress Promotion For 2015 2Health News:Energy Textiles Launches Celliant Revitalizing Bedsheets 2Health News:Narconon Arrowhead Debuts Float at Checotah and Eufaula Christmas Parades 2Health News:Narconon Arrowhead Debuts Float at Checotah and Eufaula Christmas Parades 3Health News:Mark DeMontis, Founder of Courage Canada, shares his passion for bringing hockey to those affected by blindness in Mediaplanet’s “Vision and Hearing” campaign 2Health News:E. Coli Germs Found on Farmers Market Herbs 2
... ... best hospitals in the United States by U.S. News & World Report. , ... New York, NY (Vocus) July 16, 2009 -- The Mount Sinai Medical ... States by U.S. News & World Report. , , ,In the 2009-10 America,s Best Hospital issue, Mount ...
... , BOCA RATON, Fla., July 16 JAG ... further update of the status of its acquisition of CardioGenics ... closing date for the acquisition, currently scheduled for a date ... a date on or before July 24, 2009 to allow ...
... ... their practices and prepare for the future just launched on Monday. , ... (Vocus) July 16, 2009 -- The ... 25 years of combined experience in dental practice sales and appraisals, is the first membership-based, ...
... , , WASHINGTON, July 16 ... committees crafting the House version of a health care reform bill ... those revenues to a special fund to finance prevention and wellness ... taxes are an important tool in reducing the public health toll ...
... to higher risk of heart attack, stroke, agency says, ... Food and Drug Administration has begun a safety review ... an increased risk of heart attack, abnormal heart rhythm, ... Early results from the Evaluating the Clinical Effectiveness and ...
... , , , BEDFORD, Ohio, ... Inc., announced FDA approval to begin shipping Ceftriaxone for Injection USP. ... by Roche. Ceftriaxone is a semisynthetic, broad-spectrum antibiotic used to ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20070809/CLTH157LOGO ...
Cached Medicine News:Health News:The Mount Sinai Medical Center Named to "Honor Roll" in U.S. News's 2009-10 Edition of America's Best Hospitals 2Health News:The Mount Sinai Medical Center Named to "Honor Roll" in U.S. News's 2009-10 Edition of America's Best Hospitals 3Health News:JAG Media Holdings, Inc. Announces a Further Update of the Status of Its Acquisition of CardioGenics Inc. 2Health News:National Practice Transition Network Launches as the Country's First Membership-Based, Commission-Free Dental Practice Transition Company 2Health News:Raise Federal Alcohol Tax to Finance Prevention Trust Fund, Partnership Urges House Chairmen 2Health News:FDA Investigating Safety of Asthma Drug Xolair 2Health News:Bedford Laboratories(TM) to Begin Shipping Ceftriaxone for Injection USP 2
Single-Piece PMMA IOLs for the replacement of the human crystalline lens in the visual correction of aphakia....
STABIBAG Hydrophilic Acrylic Lens....
BIGBAG Hydrophilic Acrylic Lens for high myopia....
One piece multifocal acrylic intraocular lens....
Medicine Products: